Hotchkis & Wiley Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Hotchkis & Wiley Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.6M	Buy	+447,200	New	+$24.5M	0.07%	112

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Hotchkis & Wiley Capital Management's BMRN Position: Q2 2026 in Review

Hotchkis & Wiley Capital Management opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 447,200 shares worth $25.6M. The stake represents 0.07% of the portfolio and ranks #112 among its holdings.

561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Hotchkis & Wiley Capital Management held 447,200 shares of BioMarin Pharmaceuticals worth $25.6M as of Q2 2026.
BioMarin Pharmaceuticals was a new Hotchkis & Wiley Capital Management position in Q2 2026.
BioMarin Pharmaceuticals made up 0.07% of Hotchkis & Wiley Capital Management's portfolio in Q2 2026, its #112 holding.
561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Hotchkis & Wiley Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.